risdiplam

Roche
Biotech

Roche's risdiplam clears another phase 3 SMA trial

The clinical success comes months before the FDA is set to decide whether to approve the survival motor neuron-2 splicing modifier.
Nick Paul Taylor Jan 23, 2020 7:35am